Development and validation of LC-MS method for the determination of heptaethylene glycol monomethyl ether in benzonatate bulk drugs.
Lakshmi Narasimha Rao KatakamSanthosh Kumar EttaboinaVishnu Murthy MarisettiPublished in: Biomedical chromatography : BMC (2021)
A simple and isocratic reverse-phase liquid chromatography with mass spectrometric method has been developed and validated for the determination of heptaethylene glycol monomethyl ether in benzonatate drug substance. Benzonatate is an oral antitussive drug used to relieve and suppress cough in patients older than 10 years. The presence of residual heptaethylene glycol monomethyl ether in the benzonatate drug substance affects the safety, strength, purity and quality of the drug substance. The subject compound separation was achieved using 0.1% formic acid and acetonitrile (50:50 v/v) at a flow rate of 0.3 ml/min. The Suplex PKB-100 250 × 4.6 mm, 5 μm LC column was used for a better peak shape. Detection was carried out at an m/z value of 341. The linearity curve showed a correlation of coefficient of >0.999. The precision and intermediate precision (RSD) were <7.30. The accuracy values were >90% for all levels. The developed method was validated as per International Conference on Harmonization guidelines and found to be a novel, specific and sensitive analytical method for determination of components of interest.
Keyphrases
- liquid chromatography
- solid phase extraction
- mass spectrometry
- high resolution mass spectrometry
- end stage renal disease
- tandem mass spectrometry
- molecularly imprinted
- adverse drug
- simultaneous determination
- chronic kidney disease
- drug induced
- ejection fraction
- emergency department
- magnetic resonance imaging
- physical activity
- peritoneal dialysis
- quality improvement
- patient reported
- sensitive detection